PR86849

TEL AVIV, Israel and RALEIGH, N.C., Nov. 25, 2020 /PRNewswire=KYODO JBN/ --

RedHill Biopharma Ltd. (https://www.redhillbio.com/RedHill/ ) (Nasdaq: RDHL)

("RedHill" or the "Company"), a specialty biopharmaceutical company, today

announced that it will present and participate at the following virtual

conferences in December:

Logo - https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg

Evercore ISI 3rd Annual HealthCONx Conference

Fireside chat and an open Q&A: Thursday, December 3, 2020, 8 a.m. EST

Moderator: Umer Raffat, Equity Research – Biotech-large, Pharma-major,

Specialty Pharma

Speaker: Dror Ben-Asher, CEO & Gilead Raday, Chief Operating Officer

Piper Sandler 32nd Annual Virtual Healthcare Conference

Fireside chat: Available on-demand from November 23, 2020

Moderator: David Amsellem, Managing Director, Sr. Research Analyst, Specialty

Pharma

Speaker: Guy Goldberg, Chief Business Officer

The webcasts will be available for replay for 30 days on the Company's website:

https://ir.redhillbio.com.

About RedHill Biopharma    

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company

primarily focused on gastrointestinal and infectious diseases. RedHill promotes

the gastrointestinal drugs, Movantik(R) for opioid-induced constipation in

adults with non-cancer pain[1], Talicia(R) for the treatment of Helicobacter

pylori (H. pylori) infection in adults[2], and Aemcolo(R) for the treatment of

travelers' diarrhea in adults[3]. RedHill's key clinical late-stage

investigational development programs include: (i) RHB-204, with an ongoing

Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii)

opaganib (Yeliva(R)), a first-in-class SK2 selective inhibitor targeting

multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies

for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-104, with

positive results from a first Phase 3 study for Crohn's disease; (iv) RHB-102

(Bekinda(R)), with positive results from a Phase 3 study for acute

gastroenteritis and gastritis and positive results from a Phase 2 study for

IBS-D; (v) RHB-107 (upamostat), a Phase 2-stage first-in-class, serine protease

inhibitor, targeting cancer and inflammatory gastrointestinal diseases and is

also being evaluated for COVID-19 and (vi) RHB-106, an encapsulated bowel

preparation. More information about the Company is available at

www.redhillbio.com.

This press release contains "forward-looking statements" within the meaning of

the Private Securities Litigation Reform Act of 1995. Such statements may be

preceded by the words "intends," "may," "will," "plans," "expects,"

"anticipates," "projects," "predicts," "estimates," "aims," "believes,"

"hopes," "potential" or similar words. Forward-looking statements are based on

certain assumptions and are subject to various known and unknown risks and

uncertainties, many of which are beyond the Company's control and cannot be

predicted or quantified, and consequently, actual results may differ materially

from those expressed or implied by such forward-looking statements. Such risks

and uncertainties include risks and uncertainties associated with (i) the

initiation, timing, progress and results of the Company's research,

manufacturing, preclinical studies, clinical trials, and other therapeutic

candidate development efforts, and the timing of the commercial launch of its

commercial products and ones it may acquire or develop in the future; (ii) the

Company's ability to advance its therapeutic candidates into clinical trials or

to successfully complete its preclinical studies or clinical trials (iii) the

extent and number and type of additional studies that the Company may be

required to conduct and the Company's receipt of regulatory approvals for its

therapeutic candidates, and the timing of other regulatory filings, approvals

and feedback; (iv) the manufacturing, clinical development, commercialization,

and market acceptance of the Company's therapeutic candidates and Talicia(R);

(v) the Company's ability to successfully commercialize and promote

Movantik(R), Talicia(R) and Aemcolo(R); (vi) the Company's ability to establish

and maintain corporate collaborations; (vii) the Company's ability to acquire

products approved for marketing in the U.S. that achieve commercial success and

build and sustain its own marketing and commercialization capabilities; (viii)

the interpretation of the properties and characteristics of the Company's

therapeutic candidates and the results obtained with its therapeutic candidates

in research, preclinical studies or clinical trials; (ix) the implementation of

the Company's business model, strategic plans for its business and therapeutic

candidates; (x) the scope of protection the Company is able to establish and

maintain for intellectual property rights covering its therapeutic candidates

and commercial products and its ability to operate its business without

infringing the intellectual property rights of others; (xi) parties from whom

the Company licenses its intellectual property defaulting in their obligations

to the Company; (xii) estimates of the Company's expenses, future revenues,

capital requirements and needs for additional financing; (xiii) the effect of

patients suffering adverse events using investigative drugs under the Company's

Expanded Access Program; and (xiv) competition from other companies and

technologies within the Company's industry. More detailed information about the

Company and the risk factors that may affect the realization of forward-looking

statements is set forth in the Company's filings with the Securities and

Exchange Commission (SEC), including the Company's Annual Report on Form 20-F

filed with the SEC on March 4, 2020. All forward-looking statements included in

this press release are made only as of the date of this press release. The

Company assumes no obligation to update any written or oral forward-looking

statement, whether as a result of new information, future events or otherwise

unless required by law.

Company contact:                                    Media contact (U.S.):

Adi Frish                                                   Bryan Gibbs

Chief Corporate &                                    Vice President

Business Development Officer                Finn Partners

RedHill Biopharma                                  +1 212 529 2236

+972-54-6543-112                                  bryan.gibbs@finnpartners.com

adi@redhillbio.com

[1] Full prescribing information for Movantik(R) (naloxegol) is available at:

www.Movantik.com.  

[2] Full prescribing information for Talicia(R) (omeprazole magnesium,

amoxicillin and rifabutin) is available at: www.Talicia.com.      

[3] Full prescribing information for Aemcolo(R) (rifamycin) is available at:

www.Aemcolo.com.

SOURCE:  RedHill Biopharma Ltd.